Alert detail
FDA Approval: TRUTAKNA (atacicept-vymj) — Type 1 - New Molecular Entity
Policy ID: FDA-BLA761486Specialty: RheumatologyAdded: 7/11/2026Effective: July 7, 2026billing update
What changed
New subcutaneous NME; watch for Part B J-code assignment.
Who’s affected: Rheumatology billing teams · Effective: July 7, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.